XPLAZO Trademark

Trademark Overview

On Friday, September 1, 2023, a trademark application was filed for XPLAZO with the United States Patent and Trademark Office. The USPTO has given the XPLAZO trademark a serial number of 79381364. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Tuesday, August 27, 2024. This trademark is owned by CSL Behring AG. The XPLAZO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for cardiovascular diseases, illnesses, and conditions; Pharmaceutical preparations for infusion conditions; pharmaceutical preparations for cardiovascular conditions and blood conditions, namely, novel, plasma derived apolipoprotein A-I conditions while undergoing infusion therapy; pharmaceutical preparations for novel apolipoprotein A-I infusion therapy to potentially reduce the risk of recurrent major adverse cardiovascular events, MACE, in patients within 90 days of an acute myocardial infarction, AMI, with a sustained benefit for 365 days; Pharmaceutical preparations for acute myocardial infarction, AMI, Pharmaceutical preparations for cardiovascular diseases; pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; Pharmaceutical preparations for the treatment and prevention of blood ...
xplazo

General Information

Serial Number79381364
Word MarkXPLAZO
Filing DateFriday, September 1, 2023
Status681 - PUBLICATION/ISSUE REVIEW COMPLETE
Status DateTuesday, August 27, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 1, 2024

Trademark Statements

Goods and ServicesPharmaceutical preparations for cardiovascular diseases, illnesses, and conditions; Pharmaceutical preparations for infusion conditions; pharmaceutical preparations for cardiovascular conditions and blood conditions, namely, novel, plasma derived apolipoprotein A-I conditions while undergoing infusion therapy; pharmaceutical preparations for novel apolipoprotein A-I infusion therapy to potentially reduce the risk of recurrent major adverse cardiovascular events, MACE, in patients within 90 days of an acute myocardial infarction, AMI, with a sustained benefit for 365 days; Pharmaceutical preparations for acute myocardial infarction, AMI, Pharmaceutical preparations for cardiovascular diseases; pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, October 20, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCSL Behring AG
Party Type10 - Original Applicant
Legal Entity Type25 - NOT AVAILABLE
AddressCH

Trademark Events

Event DateEvent Description
Thursday, October 19, 2023SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, October 20, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, October 24, 2023APPLICATION FILING RECEIPT MAILED
Wednesday, February 14, 2024TEAS VOLUNTARY AMENDMENT RECEIVED
Tuesday, April 30, 2024ASSIGNED TO EXAMINER
Monday, May 6, 2024NON-FINAL ACTION WRITTEN
Tuesday, May 7, 2024NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, May 15, 2024REFUSAL PROCESSED BY MPU
Tuesday, June 11, 2024REFUSAL PROCESSED BY IB
Monday, August 26, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, August 26, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, August 26, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, August 26, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, September 11, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, May 15, 2024NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

Related Keywords

xplazo preparations pharmaceutical conditions cardiovascular infusion myocardial deficiency days acute infarction